Ot­su­ka gob­bles up more glob­al rights for Ake­bia’s vadadu­s­tat, chip­ping in to a pot now worth $2B-plus

Late last year Ot­su­ka stepped in with a deal worth more than a bil­lion dol­lars to part­ner with Ake­bia on its ex­per­i­men­tal ane­mia drug vadadu­s­tat in the US mar­ket. But the pact ev­i­dent­ly on­ly whet­ted its ap­petite for more.

In a deal ex­ten­sion an­nounced af­ter the mar­ket closed on Tues­day, Ot­su­ka came back to grab Eu­rope, Chi­na, Rus­sia and much of the rest of the world, pay­ing an­oth­er $208 mil­lion in com­mit­ted cap­i­tal cov­er­ing $73 mil­lion up­front and $135 mil­lion to cov­er de­vel­op­ment costs. There’s al­so $657 mil­lion in po­ten­tial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER